VIR Vir Biotechnology Inc

Price (delayed)

$7

Market cap

$960M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.83

Enterprise value

$737.81M

Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are ...

Highlights
The debt has contracted by 19% YoY and by 3.5% from the previous quarter
The EPS rose by 17% year-on-year and by 2.3% since the previous quarter
Vir Biotechnology's equity has decreased by 28% YoY and by 7% from the previous quarter
VIR's revenue is down by 14% YoY and by 6% from the previous quarter

Key stats

What are the main financial stats of VIR
Market
Shares outstanding
137.14M
Market cap
$960M
Enterprise value
$737.81M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.84
Price to sales (P/S)
12.85
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.94
Earnings
Revenue
$74.21M
Gross profit
$73.36M
Operating income
-$587.17M
Net income
-$521.96M
EBIT
-$523.11M
EBITDA
-$503.3M
Free cash flow
-$450.28M
Per share
EPS
-$3.83
EPS diluted
-$3.83
Free cash flow per share
-$3.3
Book value per share
$8.35
Revenue per share
$0.54
TBVPS
$10.08
Balance sheet
Total assets
$1.4B
Total liabilities
$248.43M
Debt
$90.14M
Equity
$1.15B
Working capital
$922.8M
Liquidity
Debt to equity
0.08
Current ratio
8.71
Quick ratio
8.31
Net debt/EBITDA
0.44
Margins
EBITDA margin
-678.3%
Gross margin
98.9%
Net margin
-703.4%
Operating margin
-791.3%
Efficiency
Return on assets
-32.8%
Return on equity
-38.9%
Return on invested capital
-40.8%
Return on capital employed
-40.9%
Return on sales
-704.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VIR stock price

How has the Vir Biotechnology stock price performed over time
Intraday
-4.44%
1 week
-13.26%
1 month
-26.93%
1 year
-36.07%
YTD
-4.63%
QTD
-4.63%

Financial performance

How have Vir Biotechnology's revenue and profit performed over time
Revenue
$74.21M
Gross profit
$73.36M
Operating income
-$587.17M
Net income
-$521.96M
Gross margin
98.9%
Net margin
-703.4%
The net income has increased by 15% year-on-year and by 2.1% since the previous quarter
The company's operating income rose by 14% YoY and by 3.6% QoQ
VIR's revenue is down by 14% YoY and by 6% from the previous quarter
The company's gross profit fell by 12% YoY and by 6% QoQ

Growth

What is Vir Biotechnology's growth rate over time

Valuation

What is Vir Biotechnology stock price valuation
P/E
N/A
P/B
0.84
P/S
12.85
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.94
The EPS rose by 17% year-on-year and by 2.3% since the previous quarter
VIR's price to book (P/B) is 77% lower than its 5-year quarterly average of 3.6 and 7% lower than its last 4 quarters average of 0.9
Vir Biotechnology's equity has decreased by 28% YoY and by 7% from the previous quarter
The price to sales (P/S) is 67% lower than the 5-year quarterly average of 39.1 and 13% lower than the last 4 quarters average of 14.8
VIR's revenue is down by 14% YoY and by 6% from the previous quarter

Efficiency

How efficient is Vir Biotechnology business performance
Vir Biotechnology's return on assets has decreased by 18% YoY and by 6% QoQ
Vir Biotechnology's return on equity has decreased by 11% YoY and by 6% QoQ
The return on invested capital has declined by 7% since the previous quarter but it rose by 4.4% year-on-year
The return on sales rose by 3.3% year-on-year but it has declined by 2.8% since the previous quarter

Dividends

What is VIR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VIR.

Financial health

How did Vir Biotechnology financials performed over time
Vir Biotechnology's total assets has decreased by 27% YoY and by 7% QoQ
The company's total liabilities fell by 24% YoY and by 3.6% QoQ
The debt is 92% less than the equity
Vir Biotechnology's equity has decreased by 28% YoY and by 7% from the previous quarter
The debt has contracted by 19% YoY and by 3.5% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.